Summary Engineering of a variety of rodent tumour cells to secrete either interleukin 2 (IL-2), or interleukin 4 (IL-4), has been demonstrated to reduce their tumorigenicity. However the mechanisms of action of secreted IL-2 and IL-4 have not been compared in a single rodent tumour. Here we demonstrate that the weakly immunogenic murine fibrosarcoma FS29 had reduced growth rate and in some cases was rejected by syngeneic animals, when modified to secrete either IL-2 or IL-4, but not IL-5. Immunohistochemical analysis of tumour nodules undergoing regression showed stimulation of a largely lymphocytic infiltrate by IL-2 and a macrophage and granulocyte infiltrate, with a small number of lymphocytes by IL-4. Indeed, secretion of low levels of IL-2 and IL-4 in combination resulted in optimal rejection, suggesting that the two cytokines might mobilise different and complementary effector cell mechanisms. Both IL-2 and IL-4-secreting cells failed to induce the rejection of admixed, unmodified FS29 cells. The loss of cytokine secreting cells from such admixtures occurred more rapidly for IL-2-secreting cells. Injection of IL-4-secreting, but not IL-2-secreting FS29 cells could protect mice from a delayed challenge with unmodified FS29 cells. These data suggest that IL-4 secretion stimulates the better long-term host anti-tumour response.
Observations that rodents from which a primary, syngeneic tumour had been excised could be resistant to a secondary tumour challenge (Prehn & Main, 1957; Klein et al., 1960) led to the proposition that a specific host anti-tumour immune response could be stimulated. Subsequent studies have demonstrated that the stimulation of tumour specific cytotoxic T lymphocytes (CTLs) (Boon et al., 1980; Brunner et al., 1981 ) is important in eliciting tumour rejection in rodent models (Uyttenhove et al., 1983) . Several approaches to the treatment of human tumours have aimed to boost what may be a sub-optimal patient anti-tumour immune response. The systemic administration of IL-2, a stimulatory factor for many cells of the immune system (Smith, 1988) , to patients with metastatic melanoma and renal cell carcinoma, showed some therapeutic effect (Rosenberg et al., 1989) . However, toxic side-effects were observed at the high concentrations required (Rosenberg et al., 1989) . A further strategy has been the use of irradiated patient tumour cells, rendered more antigenic by viral infection, as a potential vaccine to protect against metastases (Bohle et al., 1990) . Viral infection (Lindenmann & Klein, 1967; Kobayashi et al., 1969; Boone & Blackman, 1972; Ito et al., 1990) or the expression of recombinant viral antigens (Fearon et al., 1988; Sugiura et al., 1988) , or MHC molecules (Hui et al., 1984; Tanaka et al., 1985; Wallich et al., 1985) , has proved successful in the enhancement of immunogenicity of rodent tumour cells.
To overcome the toxicity of systemic cytokine administration, the effect of engineering rodent tumour cells to secrete cytokines locally has been examined. Secretion of IL-2 (Fearon et al., 1990; Russell et al., 1991; Ley et al., 1991) , (Tepper et al., 1989; Golumbek et al., 1991) , y-interferon ('y-IFN) (Watanabe et al., 1989; Esumi et al., 1991) , tumour necrosis factor-a (TNF-a) (Asher et al., 1991; Blankenstein et al., 1991) , granulocyte colony stimulating factor (Colombo et al., 1991) , or interleukin 7 (Hock et al., 1991; McBride et al., 1992) (Miller, 1992) . As gene delivery to all cells within a tumour will probably not be feasible, cytokine secretion by some cells within a tumour would have to lead to the rejection of adjacent, unmodified cells for direct cytokine gene delivery to be effective. An effect on the rejection of admixed, unmodified cells has been reported for IL-2 Ley et al., 1991; ) , IL-4 (Tepper et al., 1989; Golumbek et al., 1991) and TNF-a (Asher et al., 1991) -secreting rodent tumour cells.
The second therapeutic use of cytokine-secreting tumour cells would be as an injection post primary tumour excision, to enhance the elimination of minimal residual disease. This would require the culture of cells from resected tumour material and their in vitro modification to secrete cytokines, followed by re-injection. Another human gene therapy trial is employing this approach with IL-2 and TNF-a-secreting tumour cells (Rosenberg et al., 1992a; Rosenberg, 1992b) . In rodent tumour studies IL-2 Ley et al., 1991) , (Golumbek et al., 1991) and y-IFN (Watanabe et al., 1989; )-secreting tumour cells have each been shown to induce protection against parental tumour cell challenge. In order to determine which of these therapeutic routes might be the more feasible, we have compared the properties of IL-2 and IL-4-secreting tumour cells in a single murine tumour, the transplantable fibrosarcoma, FS29 (Eccles et al., 1980) . We have demonstrated that either IL-2, or IL-4-secreting cells show a poor ability to induce the rejection of admixed parental cells. This failure can be ascribed to a rapid loss of the secreting cells from tumours. However, IL-4-secreting FS29 cells showed a greatly enhanced ability to protect animals against subsequent parental tumour challenge, when compared with IL-2-secreting, or parental cell injections.
Methods and materials
Cell lines FS29 is a benzpyrene induced murine sarcoma cell line (Eccles et al., 1980 ) that was grown in vitro as an adherent monolayer in DMEM with 10% fetal calf serum (FCS).
PA317 (Miller & Buttimore, 1986) and GP + envAM12 (Markowitz et al., 1988) amphotropic retroviral packaging cell lines were grown as adherent monolayers in DMEM and 10% newborn calf serum. IL-2-dependent CTLL-2 (Gillis & Smith, 1977) and IL-2-dependent, IL-4-responsive HT-2 (Lichtman et al., 1987) Plasmids and recombinant retroviruses The plasmid pZipNeoSV(X) (Cepko et al., 1984) , pZipNeoSVIL-2 (Yamada et al., 1987) , containing the human IL-2 cDNA, pZipNeoSVIL-4, containing a murine cDNA (which was constructed by ligating a series of synthetic oligonucleotides to give an identical amino-acid sequence to that produced by the published murine cDNA (Lee et al., 1986) ) and pZipNeoSVIL-5 containing the murine IL-5 cDNA (Campbell et al., 1987) were transfected by calcium phosphate precipitation into PA317 or GP + env-AM12 packaging cell lines. G418 resistant colonies were picked and assayed for recombinant retrovirus production and absence of helper virus as described previously (Danos, 1991 (Danos, 1991 anti-IL-2 blocking antiserum (New Brunswick Scientific, UK) for 2 h prior to testing. IL-5 was measured as previously described (Strath et al., 1985) . Table  I details the level of human IL-2, murine IL-2, murine IL-4, or murine IL-5 produced in vitro by cell clones, selected as secretors of the highest levels of cytokine. Cytokine secretion did not affect the growth rate of the clones in vitro and the levels of cytokine secreted were unchanged following prolonged passage of the cell clones in culture (data not shown). All clones expressed very low or undetectable levels of MHC Figure 1 shows a typical experiment for each clone and a compilation of all experiments is presented in Table I . FS29IL-2.1 which secreted the highest level of IL-2, formed an initial tumour nodule which then regressed completely in most animals. Those clones secreting less IL-2, FS29IL-2.2 and FS29muIL-2.7 showed some delay in growth compared to FS29Neo cells, but ultimately formed tumours in -the majority of animals. Tumours which arose from the IL-2-secreting cell clones were explanted, cultured and assessed for their ability to secrete IL-2. In every case the explanted tumour cells secreted considerably reduced, or no, IL-2 (Table I ). This could be attributed to a decrease in the IL-2-encoding retroviral integrant in each case ( Figure 5 , upper panel, track 4 and data not shown). Thus, a strong selective pressure against both human and murine IL-2 secretion in vivo resulted in rapid selection of cells within the tumour which had lost the retroviral integrant. This selection was not observed upon growth of FS29IL-2.1 in athymic mice ( Figure 5 , upper panel, track 3).
The three IL-4-secreting FS29 clones also displayed slower growth rates and reduced tumorigenicity in syngeneic mice ( Figure 1 and Table I ). One clone, FS29IL-4.2, formed small nodules and then regressed in most animals. Two further clones, FS29IL-4.1 and FS29IL-4.S, formed small tumours which persisted for prolonged periods, in contrast to the IL-2 secreting clones. When such persistent tumours were explanted and their IL-4-secretion was measured, it was found that they secreted unreduced levels of IL-4 (Table I) and retained the IL-4 encoding retroviral integrant ( Figure 5 , lower panel, track 5). In contrast to previous reports (Tepper et al., 1989; Golumbek et al., 1991) , IL-4 secretion did not affect the growth rate of FS29 cells in athymic mice (data not shown). IL-4 secretion, by murine plasmacytoma, adenocarcinoma or renal cell carcinoma cells had previously been reported to induce an eosinophilic infiltrate in vivo (Tepper et al., 1989; Golumbek et al., 1991) , and anti-IL-5 antibodies had been shown to partially restore the tumorigenicity of IL-4-secreting cells (Tepper et al., 1992) . Therefore, we monitored the effect of secretion of IL-5, the major growth factor for cells of the eosinophil lineage, upon FS29 tumour formation. Figure 1 shows that IL-5 secretion did not cause any slowing of tumour growth in syngeneic animals; no eosinophil infiltrate was observed in IL-5-secreting tumours (data not shown). To observe the effect of simultaneous IL-2 and IL-4 secretion, a doubly-transfected clone secreting suboptimal levels of both cytokines was isolated. Additional secretion of IL-2, by the non-rejecting IL-4 secreting clone IL-4.1, was able to induce tumour rejection (Table I ). This co-operative effect suggested that the two cytokines might act by mobilisation of different effector mechanisms. the IL-2-secreting tumours (Figure 2 ). The majority of these cells were CD8 +, with some CD4 + cells and B cells (Table  II) . In contrast, the IL-4-secreting tumours were characterised by a macrophage and granulocyte infiltrate, with a small number of CD8 + and CD4 + lymphocytes (Figure 2 , Table II ). This inflammatory cell infiltrate was not observed in IL-4-secreting tumour nodules from athymic animals ( Figure 2 ) and thus appears to be dependent on a T lymphocyte response.
Cytokine-secreting cells are selectively lost from tumours To assess the potential of cytokine gene delivery to existing tumours in vivo as a tumour therapy, the ability of cytokinesecreting FS29 cells to induce rejection of admixed, unmodified cells was measured. Figure 3 shows that neither IL-2, nor IL-4-secreting FS29 cells caused any slowing of growth of an equal number of admixed non-secreting FS29 cells. When the IL-2, or IL-4-secreting cells were present in a 10-fold excess, initial delay in the growth of the unmodified cells was observed, but rapidly growing tumours eventually formed in all animals ( Figure 3 ). These data are in contrast to several previous studies, which have demonstrated effective induction of parental tumour rejection by admixture of 50% IL-2 Ley et al., 1991) , or IL-4-secreting cells (Tepper et al., 1989; Golumbek et al., 1991) .
To investigate the reason for this lack of effect of cytokine secretion on adjacent unmodified FS29 cells, tumour nodules were explanted soon after injection of IL-2 and parental cell admixtures. When the level of IL-2 secretion from such explanted cells was analysed, admixtures of IL-2-secreting and parental cells were found still to secrete IL-2 after 7 days in vivo growth (Figure 4) . However, following 14 days of tumour development, IL-2 secretion was lost (Figure 4 ). This correlated with loss of IL-2-encoding retroviral DNA sequences, which could be detected after 7 days but not 14 days tumour growth, in the explanted cells ( Figure 5 provides an explanation for the inability of such cytokine secreting FS29 cells to induce rejection of admixed parental cells. These data suggest that direct retroviral-mediated cytokine gene delivery to tumour cells in vivo will not be able to induce tumour rejection, even if delivery to over 50% of cells within a tumour were feasible.
IL-4-secreting cells can protect animals from parental tumour challenge. An alternative application of retroviral cytokine gene delivery in cancer therapy would be the use of tumour cells, cultured following primary lesion excision and infected with cytokine-encoding retroviruses, as an injection to enhance eradication of minimal residual disease. days. In contrast, parental cell injection afforded no lasting protection, confirming the weak basal immunogenicity of this tumour ( Figure 6 ). IL-2-secreting tumour cells also did not protect animals against delayed parental cell challenge ( Figure 6 ). These data suggest that IL-4-secreting tumour cells, while unable to induce a rapid enough immune response to cause the rejection of admixed parental cells, can stimulate an effective long-term anti-tumour response. This study represents a detailed comparison of the effects of IL-2 and IL-4 secreted by the same tumour. Secretion of a sufficiently high level of IL-2 by FS29 cells resulted in tumour rejection, whereas lower levels of secretion slowed initial growth but resulted in the later appearance of rapidly growing tumours. This could be explained by the loss of the IL-2 transgene and thus IL-2 secretion by these outgrowing cells, which suggests that a strong selective pressure against IL-2 secretion occurred in syngeneic animals. Loss of cytokine was observed with tumour cells secreting either human, or murine IL-2. A similar selection against IL-2 secretion was previously observed in the rat tumour HSN when passaged in syngeneic immunocompetent, but not athymic, animals (Russell et al., 1991 (10), FS29IL-4.2 + FS29IL-2.1 day 14 (11). (Golumbek et al., 1991; Tepper et al., 1989) secreting, or parental tumour injected animals showed no protection after this period. From analysis of the host cell infiltrate in tumour nodules undergoing rejection, IL-4 and IL-2 were clearly stimulating different subsets of cells. IL-2 recruited largely CD8 + lymphocytes, whereas IL-4 stimulated macrophages, granulocytes, and some lymphocytes. Indeed, secretion of both IL-2 and IL-4 by the same cell led to enhanced tumour rejection. The stimulation of an inflammatory infiltrate by IL-4 has previously been reported in a murine plasmocytoma (Tepper et al., 1989) , murine adenocarcinoma (Tepper et al., 1989 ) and murine renal cell carcinoma (Golumbek et al., 1991) . The importance of such an infiltrate has been demonstrated by the inhibition of tumour rejection in the presence of anti-granulocyte antibodies (Tepper et al., 1992) . However in previous studies IL-4 slowed tumour growth, or led to tumour rejection in immunodeficient animals where a similar infiltrate was observed (Tepper et al., 1989; Tepper et al., 1992) . As a variety of cell types express receptors for IL-4 (Paul, 1991) , a direct effect of this cytokine on the growth of some tumours may be possible. (Golumbek et al., 1991) . However, another report describes a complete absence of induction of protection by IL-4-secreting plasmacytoma cells (Tepper et al., 1992) . Two reports described lasting protection induced by IL-2-secreting cells Ley et al., 1991) , the work of Ley et al. (Ley et al., 1991) demonstrated an enhanced protection compared to parental mastocytoma cells. The study of Fearon et al. described short-term protection induced by IL-2-secreting colon tumour cells which is greatly diminished after 28 days (Fearon et al., 1990 ). Such differences observed in previous studies might be ascribed to differential intrinsic immunogenicity of the various tumours. Our direct comparison, in the FS29 sarcoma model, suggests that IL-4-secreting cells provide the better protection. The greater protective response induced by IL-4 may be partly explained by two of our observations. Firstly, IL-4 recruits different subsets of host immune cells, as demonstrated by the different infiltrate observed in IL-4 compared with IL-2-secreting tumours. Some of the cells recruited by IL-4, but not by IL-2, may be important to the establishment of a long-term anti-tumour response. Secondly, as IL-4-secreting cells suffer a less stringent host immune selection, IL-4-secreting tumour cells are maintained for longer than their IL-2 counterparts. This longer period of immune stimulation may also be important in the generation of a greater response.
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